Table 1.

Demographics based on ESA use during the baseline perioda

VariableNo ESA Use (n = 3143)On ESA Throughout (n = 1823)Commenced ESA (n = 1199)Total (n = 6165)P
Age (yr; mean ± SD)68.5 ± 13.270.0 ± 14.368.9 ± 13.769.0 ± 13.70.0008
Male (%)61.651.153.556.9<0.0001
Race (%)<0.0001
        white78.866.769.773.3
        Asian15.828.023.521.1
        other5.45.36.85.6
GFR (ml/min per 1.73 m2; mean ± SD)27.7 ± 11.323.8 ± 10.821.9 ± 10.125.4 ± 11.2<0.0001
        30 to 60 (%)40.227.520.632.6
        15 to 30 (%)47.449.852.549.1
        <15 (%)12.422.827.018.3
Hemoglobin (g/L; mean ± SD)125.0 ± 15.7110.9 ± 15.5103.0 ± 12.6116.5 ± 17.6<0.0001
Diabetes (%)36.534.138.736.20.038
Follow-up (mo; mean ± SD)34.6 ± 15.034.6 ± 17.431.3 ± 15.034.0 ± 15.8<0.0001
Hb measurements during baseline period
    n (range)4 (3 to 7)4 (3 to 7)5 (3 to 7)5 (3 to 7)
    mean ± SD4.52 ± 1.374.09 ± 1.234.83 ± 1.345.05 ± 1.38<0.0001
  • a ESA, erythropoiesis-stimulating agent; Hb, hemoglobin.